{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:57:31Z","timestamp":1788587851941,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jsat.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T23:47:59Z","timestamp":1532130479000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Comparison between buprenorphine provider availability and opioid deaths among US counties"],"prefix":"10.1016","volume":"93","author":[{"given":"Christopher W.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Christman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle R.","family":"Safferman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-401X","authenticated-orcid":false,"given":"Kaitlan","family":"Baston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Haroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsat.2018.07.008_bb0005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2018.07.008_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder","volume":"15","author":"Andrilla","year":"2017","journal-title":"Annals of Family Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2018.07.008_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1538-4632.1995.tb00338.x","article-title":"Local indicators of spatial association","volume":"27","author":"Anselin","year":"1995","journal-title":"Geographical Analysis"},{"issue":"2","key":"10.1016\/j.jsat.2018.07.008_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","article-title":"Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians","volume":"39","author":"Arfken","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2018.07.008_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6504a1","article-title":"Surveillance for certain health behaviors, chronic diseases, and conditions, access to health care, and use of preventive health services among states and selected local areas - behavioral risk factor surveillance system, United States, 2012","volume":"65","author":"Chowdhury","year":"2016","journal-title":"MMWR Surveillance Summaries"},{"issue":"2S","key":"10.1016\/j.jsat.2018.07.008_bb0030","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1016\/j.japh.2016.11.007","article-title":"State legal innovations to encourage naloxone dispensing","volume":"57","author":"Davis","year":"2017","journal-title":"Journal of the American Pharmaceutical Association"},{"issue":"3","key":"10.1016\/j.jsat.2018.07.008_bb0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1160\/th15-07-0532","article-title":"Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature","volume":"115","author":"Di Minno","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1016\/j.jsat.2018.07.008_bb0040","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1377\/hlthaff.2014.1205","article-title":"Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11","volume":"34","author":"Dick","year":"2015","journal-title":"Health Affairs"},{"key":"10.1016\/j.jsat.2018.07.008_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.15971","article-title":"Underlying factors in drug overdose deaths","author":"Dowell","year":"2017","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1016\/j.jsat.2018.07.008_bb0050","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.jsat.2018.07.008_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004145.pub3","article-title":"Substitution treatment of injecting opioid users for prevention of HIV infection","volume":"2","author":"Gowing","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1016\/j.jsat.2018.07.008_bb0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.mlr.0000129906.95881.83","article-title":"Variation in access to health care for different racial\/ethnic groups by the racial\/ethnic composition of an individual's county of residence","volume":"42","author":"Haas","year":"2004","journal-title":"Medical Care"},{"issue":"4","key":"10.1016\/j.jsat.2018.07.008_bb0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/add.13238","article-title":"Long-term outcomes after randomization to buprenorphine\/naloxone versus methadone in a multi-site trial","volume":"111","author":"Hser","year":"2016","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2018.07.008_bb0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2018.07.008_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren't physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.jsat.2018.07.008_bb0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MLR.0000000000000918","article-title":"Coverage of medications that treat opioid use disorder and opioids for pain management in marketplace plans, 2017","volume":"56","author":"Huskamp","year":"2018","journal-title":"Medical Care"},{"issue":"2","key":"10.1016\/j.jsat.2018.07.008_bb0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1370\/afm.1595","article-title":"Barriers to primary care physicians prescribing buprenorphine","volume":"12","author":"Hutchinson","year":"2014","journal-title":"Annals of Family Medicine"},{"issue":"24","key":"10.1016\/j.jsat.2018.07.008_bb0090","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.jsat.2018.07.008_bb0095","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.drugalcdep.2016.08.642","article-title":"Buprenorphine physician supply: Relationship with state-level prescription opioid mortality","volume":"173","author":"Knudsen","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2018.07.008_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care-based models for the treatment of opioid use disorder: A scoping review","volume":"166","author":"Korthuis","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"10118","key":"10.1016\/j.jsat.2018.07.008_bb0105","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jsat.2018.07.008_bb0110","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.2105\/AJPH.88.7.1074","article-title":"Income inequality and mortality in metropolitan areas of the United States","volume":"88","author":"Lynch","year":"1998","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2018.07.008_bb0115","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2018.07.008_bb0120","first-page":"1","article-title":"Medication-assisted treatment for opioid addiction in the United States: Critique and commentary","author":"McElrath","year":"2017","journal-title":"Substance Use & Misuse"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2018.07.008_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/biomet\/37.1-2.17","article-title":"Notes on continuous stochastic phenomena","volume":"37","author":"Moran","year":"1950","journal-title":"Biometrika"},{"key":"10.1016\/j.jsat.2018.07.008_bb0130","article-title":"Access to and payment for office-based buprenorphine treatment in Ohio","volume":"11","author":"Parran","year":"2017","journal-title":"Substance Abuse"},{"key":"10.1016\/j.jsat.2018.07.008_bb0135","first-page":"1","article-title":"Overcoming impediments to OTP expansion in the United States and abroad","author":"Parrino","year":"2017","journal-title":"Substance Use & Misuse"},{"issue":"50\u201351","key":"10.1016\/j.jsat.2018.07.008_bb0140","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2013United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"10.1016\/j.jsat.2018.07.008_bb0145","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s13669-016-0168-9","article-title":"Caring for pregnant women with opioid use disorder in the USA: Expanding and improving treatment","volume":"5","author":"Saia","year":"2016","journal-title":"Current Obstetrics and Gynecology Reports"},{"issue":"6","key":"10.1016\/j.jsat.2018.07.008_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"10.1016\/j.jsat.2018.07.008_bb0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: The influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2018.07.008_bb0160","first-page":"1","article-title":"Utilization of buprenorphine and methadone among opioid users who inject drugs","author":"Tsui","year":"2017","journal-title":"Substance Abuse"},{"issue":"12","key":"10.1016\/j.jsat.2018.07.008_bb0165","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Archives of General Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218301983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218301983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:47:53Z","timestamp":1760039273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218301983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"alternative-id":["S0740547218301983"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2018.07.008","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison between buprenorphine provider availability and opioid deaths among US counties","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}